Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Verrica Pharmaceuticals (VRCA) Debt to Equity (2021 - 2025)

Verrica Pharmaceuticals has reported Debt to Equity over the past 4 years, most recently at -$0.73 for Q3 2025.

  • Quarterly results put Debt to Equity at -$0.73 for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was -$0.73 (changed N/A YoY), and the annual figure for FY2024 was -$1.31, changed.
  • Debt to Equity for Q3 2025 was -$0.73 at Verrica Pharmaceuticals, down from -$0.72 in the prior quarter.
  • Over the last five years, Debt to Equity for VRCA hit a ceiling of $2.59 in Q2 2022 and a floor of -$1.31 in Q4 2024.
  • Median Debt to Equity over the past 4 years was $0.72 (2021), compared with a mean of $0.45.
  • Peak annual rise in Debt to Equity hit 229.36% in 2022, while the deepest fall reached 151.13% in 2022.
  • Verrica Pharmaceuticals' Debt to Equity stood at $1.28 in 2021, then soared by 102.5% to $2.59 in 2022, then tumbled by 150.67% to -$1.31 in 2024, then skyrocketed by 44.28% to -$0.73 in 2025.
  • The last three reported values for Debt to Equity were -$0.73 (Q3 2025), -$0.72 (Q2 2025), and -$0.69 (Q1 2025) per Business Quant data.